AET 2025 On-Demand Talk: How Flexible & Robust Mammalian Cell Line Platforms Deliver Clinical Success

Hear from our VP of Research & Innovation, Dr Rob Holgate who presented at the Antibody Engineering & Therapeutics 2025 conference in San Diego on “How Flexible & Robust Mammalian Cell Line Platforms Deliver Clinical Success”

Presentation Summary

Our fully integrated AbZelectPRO™ platform enables the rapid delivery of stable, high-producing cell lines to support the production of antibodies and more difficult-to-express proteins. The platform combines our AbZelectPRO™ CHO-K1 and AbZelectPRO™-KO GS knockout cell lines together with ProteoNic’s 2G UNic® vector technology and, supported by our comprehensive analytics capabilities, provides a state-of-the-art offering to support our clients as they transition from R&D into preclinical and clinical development.

Watch the Recording